Tidepool Loop receives FDA clearance
The future of diabetes management has arrived! Tidepool Loop, the first fully interoperable automated insulin dosing app, has recently received FDA clearance. This groundbreaking development marks a major milestone in diabetes care, giving people with diabetes more control over their health and wellness.
Tidepool Loop is an innovative, patient-led initiative that provides users with an automated insulin dosing system, allowing them to manage their diabetes without having to manually adjust insulin doses. The app allows users to monitor their glucose levels in real-time and adjust insulin levels accordingly. It also gives users access to a library of personalized settings, which they can use to customize their insulin dosing to suit their individual needs.
The app is designed to be user-friendly, with a simple, intuitive interface that makes it easy to track data, view insights, and adjust settings. It also has built-in safety features like low-glucose suspend, which automatically suspends insulin delivery when a user’s glucose levels reach a certain threshold. This ensures that users are always getting the right amount of insulin, while also providing peace of mind.
Tidepool Loop is an invaluable tool for people with diabetes, providing them with greater access to health care and more control over their health and wellness. The app is also a great resource for healthcare professionals, giving them access to real-time patient data and allowing them to make more informed decisions when it comes to diabetes management.
The FDA clearance of Tidepool Loop is a groundbreaking development for diabetes care, and it will undoubtedly have a profound impact on the lives of people with diabetes. This app is a major step forward in diabetes management, providing users with greater freedom and control over their health and wellness. We’re excited to see how this innovative technology will continue to shape the future of diabetes management in the years to come.
To learn much more listen to this Juicebox Podcast interview with President, CEO and Founder of Tidepool, Howard Look.
Dexcom G7 Receives FDA Approval!
Today is the day and the Juicebox Podcast has all the info you want about the Dexcom G7.
Episode 676 - Jake Leach Executive Vice President and Chief Technology Officer at Dexcom is back to talk G7.
https://www.juiceboxpodcast.com/episodes/jbp676
Episode 782 - Emily's son has type 1 diabetes and he uses the Dexcom G7.
https://www.juiceboxpodcast.com/episodes/jbp782
Episode 768 - Dexcom Senior Director of Global Product Design, Alex Diener has type 1 diabetes and he's here to talk about designing the Dexcom G7.
https://www.juiceboxpodcast.com/episodes/jbp768
LEARN MORE ABOUT Dexcom http://bit.ly/DexAd
listen free
Apple Podcasts ⇢ http://bit.ly/JBPAPod
Spotify ⇢ http://bit.ly/JBPspot
Amazon Music ⇢ https://bit.ly/JBPAmazonMusic
Audible ⇢ https://adbl.co/3KA4J5S
Android ⇢ http://bit.ly/jbpandroid
Pandora ⇢ http://bit.ly/pandorajbp
Google Podcast ⇢ http://bit.ly/JBPgoogle
online ⇢ http://bit.ly/JuiceboxPod
Dexcom G6 App Update
Dexcom BGs right on your iPhone home screen with widgets
Know the Signs and Symptoms of Type 1 Diabetes/Conozca los síntomas de la Diabetes Typo Uno
Know the Signs and Symptoms of Type 1 Diabetes
Contact a physician immediately when symptoms are present
Frequent/Excessive urination
Unquenchable Thirst
Unexplained/Rapid weight loss
Nausea, Vomiting
Metallic or Fruity Smelling Breath
Bed-wetting
Extreme hunger
Mood changes/swings, irritability
Fatigue and weakness
Blurred vision, headache
Panting, Heavy Breathing
Press play to hear the sign and symptoms in English and Español
Conozca los síntomas de la Diabetes Typo Uno
Micción Frecuente / Orina Excesiva
Sed Insaciable
Bajo De Peso Rápido E Inexplicable
Náusea/ Vomitó
Aliento Metálico/ Frutado
Mojando La Cama
Hambre Extrema
Cambios De Humor De Repente O Irritabilidad
Fatiga Y Debilidad
Visión Borrosa, Dolores De Cabeza
Jadeó, Respirando Fuerte
Thank you to Paola Marrero for her beautiful translation
click to enlarge/share
click to enlarge/share
Dexcom G6 Covered 100% for Veterans
Dexcom G6 Continuous Glucose Monitoring System Now Available at Veterans Affairs Pharmacies Across the United States
New government contract and pharmacy availability improves access to Dexcom G6 continuous glucose monitoring for hundreds of thousands of veterans with diabetes
Prescribing Dexcom G6 is now more cost effective and efficient for the VA than the previous procurement pathway
The cost of Dexcom CGM is 100% covered by the VA for patients with Type 1 or Type 2 diabetes who meet eligibility criteria
To be eligible for Dexcom G6 coverage under Veterans Affairs, a healthcare provider must verify that the patient meets the following qualifying criteria:
Has diabetes
Performs frequent blood glucose monitoring (BGM) testing (≥4x/day)
Takes ≥3 daily injections of insulin or uses an insulin pump
Has the skillset and knowledge to use CGM successfully
Has agreed to follow up in the clinic a minimum of every 6 months
And, is one or more of the following:
At risk for hypoglycemia
Unable to meet glycemic control, despite adherence to the treatment regimen
Performs job-related activities where a hypoglycemic event could put them at risk of harm
Unable to perform self-monitoring of blood glucose due to disability or disease